ReviewPlacenta2017
Maternal immune correlates of protection against placental transmission of cytomegalovirus.
Review in Placenta, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- CD4+ but not CD8+ T cells are required for protection against severe guinea pig cytomegalovirus infections.PLoS pathogens · 2024Article
- Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024Review
- Relationship of maternal cytomegalovirus-specific antibody responses and viral load to vertical transmission risk following primary maternal infection in a rhesus macaque model.PLoS pathogens · 2023Article
- Relationship of maternal cytomegalovirus-specific antibody responses and viral load to vertical transmission risk following primary maternal infection in a rhesus macaque model.bioRxiv : the preprint server for biology · 2023Article
- Review
- Control of human cytomegalovirus replication by liver resident natural killer cells.Nature communications · 2023Article
- Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.Annual review of virology · 2022Review
- Potential of Anti-CMV Immunoglobulin Cytotect CPMicroorganisms · 2022Article
- IMGTVaccines · 2022Article
- Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs.Pathogens (Basel, Switzerland) · 2021Article
- A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.NPJ vaccines · 2021Article
- Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Hygiene promotion might be better than serological screening to deal with Cytomegalovirus infection during pregnancy: a methodological appraisal and decision analysis.BMC infectious diseases · 2020Article
- Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.The Journal of infectious diseases · 2020Article
- Review
- Article
- Seroprevalence of Cytomegalovirus Infection Among HIV-Infected and HIV-Uninfected Pregnant Women Attending Antenatal Clinic in Harare, Zimbabwe.Viral immunology · 2019Article
- Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.Journal of virology · 2019Article
- Human cord blood-derived viral pathogens as the potential threats to the hematopoietic stem cell transplantation safety: A mini review.World journal of stem cells · 2019Review
- A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.Expert review of vaccines · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Human cytomegalovirus (HCMV) is the most common congenitally transmitted pathogen worldwide, impacting an estimated 1 million newborns annually. In a subset of infected infants, congenital HCMV causes severe, long-lasting sequelae, including deafness, microcephaly, neurodevelopmental delay, and even death. Accordingly, a maternal vaccine to prevent congenital HCMV infection continues to be a top public health priority. Nevertheless, all vaccines tested to date have failed to meet clinical trial endpoints. Maternal immunity provides partial protection against congenital HCMV transmission, as vertical transmission from seropositive mothers is relatively rare. Therefore, an understanding of the maternal immune correlates of protection against HCMV congenital infection will be critical to inform design of an efficacious maternal vaccine. This review summarizes our understanding of the innate and adaptive immune correlates of protection against congenital transmission of HCMV, and discusses the advantages and applications of a novel nonhuman primate model of congenital CMV transmission to aid in rational vaccine design and evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.